Article

FDG-PET/CT in the evaluation of anal carcinoma.

Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA.
International Journal of Radiation OncologyBiologyPhysics (Impact Factor: 4.52). 08/2006; 65(3):720-5. DOI: 10.1016/j.ijrobp.2006.01.009
Source: PubMed

ABSTRACT Surgical staging and treatment of anal carcinoma has been replaced by noninvasive staging studies and combined modality therapy. In this study, we compare computed tomography (CT) and physical examination to [(18)F]-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (FDG-PET/CT) in the staging of carcinoma of the anal canal, with special emphasis on determination of spread to inguinal lymph nodes.
Between July 2003 and July 2005, 41 consecutive patients with biopsy-proved anal carcinoma underwent a complete staging evaluation including physical examination, CT, and 2-FDG-PET/CT. Patients ranged in age from 30 to 89 years. Nine men were HIV-positive. Treatment was with standard Nigro regimen.
[(18)F]-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (FDG-PET/CT) detected 91% of nonexcised primary tumors, whereas CT visualized 59%. FDG-PET/CT detected abnormal uptake in pelvic nodes of 5 patients with normal pelvic CT scans. FDG-PET/CT detected abnormal nodes in 20% of groins that were normal by CT, and in 23% without abnormality on physical examination. Furthermore, 17% of groins negative by both CT and physical examination showed abnormal uptake on FDG-PET/CT. HIV-positive patients had an increased frequency of PET-positive lymph nodes.
[(18)F]-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography detects the primary tumor more often than CT. FDG-PET/CT detects substantially more abnormal inguinal lymph nodes than are identified by standard clinical staging with CT and physical examination.

1 Bookmark
 · 
97 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: There are around 5,000 new cases of anal canal cancer each year in the United States. It is of particular risk in HIV-positive populations. Many cases are related to persistent infection with human papillomavirus (HPV). The treatment of anal cancer has progressed from abdominoperineal resection mandating permanent colostomy in the 1940s through the 1970s to modern chemoradiation with sphincter preservation in around 80% of patients, even with locally advanced disease. The evolution of the treatment paradigm of this disease is a model for the treatment of malignant disease with organ preservation. Multiple randomized trials have been conducted to guide this evolution. Technological developments in the delivery of radiotherapy and anti-cancer pharmaceuticals harbor hope for further improvements in outcomes with possible reductions in toxicity and increases in tumor control. Perhaps most inspiring is the recent development of HPV vaccines that may significantly decrease the incidence of this cancer.
    Oncology Reviews 12/2011; 3(1):27-40.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The Italian society of colo-rectal surgery (SICCR) is dedicated to improving the study, prevention and management of the diseases of the colon, rectum and anus. One of the aims of the society is to establish guidelines to the treatment of these diseases. These guidelines are based on the international literature and on the best available evidence. Clinical practice guidelines are one of the most important instruments to provide therapeutic decision-making support, based on the best scientific evidence available at the time. Guidelines are advisory and not prescriptive, susceptible to continual variations secondary to innovations and new scientific evidence. These guidelines are a guide for all colo-rectal surgeons and physicians who approach anal cancer.
    Techniques in Coloproctology 11/2012; · 1.54 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: L’objectif du traitement est d’assurer à la fois le contrôle tumoral et la préservation de la fonction sphinctérienne. Le bilan préthérapeutique s’appuie principalement sur l’examen clinique pelvien et des aires ganglionnaires inguinales, l’échoendoscopie anorectale et le scanner thoracoabdominopelvien. Il aboutit à une stadification tumorale, selon la classification TNM de l’UICC 2009, et échoendoscopique sur lesquelles repose la stratégie thérapeutique. Les principaux facteurs pronostiques sont la taille tumorale, le degré d’extension vers les structures anatomiques de voisinage, l’extension ganglionnaire ou métastatique et la réponse tumorale après une première série d’irradiation de 45 Gy en cinq semaines. La radiothérapie (RT) exclusive à visée conservatrice excluant les aires ganglionnaires inguinales jusqu’à la dose totale de 56 à 60 Gy dans le volume tumoral constitue le traitement de première intention des tumeurs classées T1N0M0 de l’UICC 2009, UST1-2, N-. Pour toutes les autres formes, le traitement de référence est l’association radiochimiothérapie (RCT) concomitante à visée curative et conservatrice avec 5-FU et mitomycine, jusqu’à la dose de 56 à 60 Gy dans le volume tumoral. L’absence de réponse tumorale supérieure à 50 % ou la persistance de troubles sphinctériens sévères (incontinence sphinctérienne, fistule anorectovaginale), après une première série d’irradiation de 45 Gy en cinq semaines, doivent faire discuter une chirurgie programmable à type d’amputation abdominopérinéale (AAP). Les intérêts de remplacer la mitomycine par le cisplatine, d’une chimiothérapie (CT) néoadjuvante, d’une CT de maintenance par cisplatine après une association RCT concomitante et d’une escalade de la dose totale d’irradiation en fonction de la réponse tumorale ne sont pas démontrés. The objective of treatment is to control locoregional disease and to preserve good anal sphincter function. Pretreatment evaluation includes mainly pelvic and inguinal clinical examination, thoracic and abdomino-pelvic CT scan, and anorectal endosonography. These assessments lead to tumor classification based on both, the clinical UICC 2009 TNM classification and the endosonography classification, which are indispensable to adopt an appropriate treatment strategy. The most important prognostic factors are: size of the tumor, tumor extension through the underlying tissue, regional lymphatic extension, distant metastatic extension, and tumor response higher than 50% after the first course of external irradiation to a total dose of 45 Gy over 5 weeks. Tumor classified T1N0M0 according to UICC 2009, UST1-2, and N-1, must be treated by curative and conservative radiotherapy alone to a total dose of 56 to 60 Gy in the tumor volume. Conservative and curative radiotherapy with concomitant chemotherapy combining 5-fluorouracil and mitomycin is a standard treatment for all other tumors, to a total dose of 56 to 60 Gy in the tumor volume. If the clinical tumor response is less than or equal to 50%, or if severe anal functional problems persist (anal incontinence, recto-vaginal fistula) after an initial course of external irradiation to a total dose of 45 Gy over 5 weeks, scheduled abdomino-perineal resection must be discussed. The impact of neoadjuvant chemotherapy, addition of maintenance chemotherapy after a combination with concomitant radio-chemotherapy, use of cisplatin in place of mitomycin, and radiation dose-escalation according to the tumor response observed after the first course of external irradiation are not demonstrated. Mots clésCarcinome épidermoïde du canal anal–Bilan préthérapeutique–Radiothérapie–Association radiochimiothérapie KeywordsEpidermoid carcinoma of the anal canal–Pretreatment evaluation–Radiotherapy–Chemo-radiotherapy
    Côlon & Rectum 5(2):58-66.